These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

884 related items for PubMed ID: 30408567

  • 1. Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects.
    Guarrera S, Viberti C, Cugliari G, Allione A, Casalone E, Betti M, Ferrante D, Aspesi A, Casadio C, Grosso F, Libener R, Piccolini E, Mirabelli D, Dianzani I, Magnani C, Matullo G.
    J Thorac Oncol; 2019 Mar; 14(3):527-539. PubMed ID: 30408567
    [Abstract] [Full Text] [Related]

  • 2. Circulating microRNAs found dysregulated in ex-exposed asbestos workers and pleural mesothelioma patients as potential new biomarkers.
    Bononi I, Comar M, Puozzo A, Stendardo M, Boschetto P, Orecchia S, Libener R, Guaschino R, Pietrobon S, Ferracin M, Negrini M, Martini F, Bovenzi M, Tognon M.
    Oncotarget; 2016 Dec 13; 7(50):82700-82711. PubMed ID: 27716620
    [Abstract] [Full Text] [Related]

  • 3. Blood cell DNA methylation biomarkers in preclinical malignant pleural mesothelioma: The EPIC prospective cohort.
    Allione A, Viberti C, Cotellessa I, Catalano C, Casalone E, Cugliari G, Russo A, Guarrera S, Mirabelli D, Sacerdote C, Gentile M, Eichelmann F, Schulze MB, Harlid S, Eriksen AK, Tjønneland A, Andersson M, Dollé MET, Van Puyvelde H, Weiderpass E, Rodriguez-Barranco M, Agudo A, Heath AK, Chirlaque MD, Truong T, Dragic D, Severi G, Sieri S, Sandanger TM, Ardanaz E, Vineis P, Matullo G.
    Int J Cancer; 2023 Feb 15; 152(4):725-737. PubMed ID: 36305648
    [Abstract] [Full Text] [Related]

  • 4. The degree of microRNA-34b/c methylation in serum-circulating DNA is associated with malignant pleural mesothelioma.
    Muraoka T, Soh J, Toyooka S, Aoe K, Fujimoto N, Hashida S, Maki Y, Tanaka N, Shien K, Furukawa M, Yamamoto H, Asano H, Tsukuda K, Kishimoto T, Otsuki T, Miyoshi S.
    Lung Cancer; 2013 Dec 15; 82(3):485-90. PubMed ID: 24168922
    [Abstract] [Full Text] [Related]

  • 5. New DNA Methylation Signals for Malignant Pleural Mesothelioma Risk Assessment.
    Cugliari G, Allione A, Russo A, Catalano C, Casalone E, Guarrera S, Grosso F, Ferrante D, Sculco M, La Vecchia M, Pirazzini C, Libener R, Mirabelli D, Magnani C, Dianzani I, Matullo G.
    Cancers (Basel); 2021 May 27; 13(11):. PubMed ID: 34071989
    [Abstract] [Full Text] [Related]

  • 6. Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer.
    Muley T, Dienemann H, Herth FJ, Thomas M, Meister M, Schneider J.
    J Thorac Oncol; 2013 Jul 27; 8(7):947-51. PubMed ID: 23777840
    [Abstract] [Full Text] [Related]

  • 7. Droplet digital PCR as a novel system for the detection of microRNA‑34b/c methylation in circulating DNA in malignant pleural mesothelioma.
    Sato H, Soh J, Aoe K, Fujimoto N, Tanaka S, Namba K, Torigoe H, Shien K, Yamamoto H, Tomida S, Tao H, Okabe K, Kishimoto T, Toyooka S.
    Int J Oncol; 2019 Jun 27; 54(6):2139-2148. PubMed ID: 30942424
    [Abstract] [Full Text] [Related]

  • 8. Changes of mesothelin and osteopontin levels over time in formerly asbestos-exposed power industry workers.
    Felten MK, Khatab K, Knoll L, Schettgen T, Müller-Berndorff H, Kraus T.
    Int Arch Occup Environ Health; 2014 Feb 27; 87(2):195-204. PubMed ID: 23423281
    [Abstract] [Full Text] [Related]

  • 9. Significance of serum mesothelin in an asbestos-exposed population in the Czech Republic.
    Jakubec P, Pelclova D, Smolkova P, Kolek V, Nakladalova M.
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Sep 27; 159(3):472-9. PubMed ID: 24781044
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma.
    Yasumitsu A, Tabata C, Tabata R, Hirayama N, Murakami A, Yamada S, Terada T, Iida S, Tamura K, Fukuoka K, Kuribayashi K, Nakano T.
    J Thorac Oncol; 2010 Apr 27; 5(4):479-83. PubMed ID: 20357617
    [Abstract] [Full Text] [Related]

  • 12. Genetic variants associated with increased risk of malignant pleural mesothelioma: a genome-wide association study.
    Matullo G, Guarrera S, Betti M, Fiorito G, Ferrante D, Voglino F, Cadby G, Di Gaetano C, Rosa F, Russo A, Hirvonen A, Casalone E, Tunesi S, Padoan M, Giordano M, Aspesi A, Casadio C, Ardissone F, Ruffini E, Betta PG, Libener R, Guaschino R, Piccolini E, Neri M, Musk AW, de Klerk NH, Hui J, Beilby J, James AL, Creaney J, Robinson BW, Mukherjee S, Palmer LJ, Mirabelli D, Ugolini D, Bonassi S, Magnani C, Dianzani I.
    PLoS One; 2013 Apr 27; 8(4):e61253. PubMed ID: 23626673
    [Abstract] [Full Text] [Related]

  • 13. DHEA-S, Androstenedione, 17-β-estradiol signature as novel biomarkers for early prediction of risk of malignant pleural mesothelioma linked to asbestos-exposure: A preliminary investigation.
    Nuvoli B, Sacconi A, Bottillo G, Sciarra F, Libener R, Maconi A, Carosi M, Piperno G, Mastropasqua E, Papale M, Camera E, Galati R.
    Biomed Pharmacother; 2024 Jun 27; 175():116662. PubMed ID: 38692064
    [Abstract] [Full Text] [Related]

  • 14. Comparison between plasma and serum osteopontin levels: usefulness in diagnosis of epithelial malignant pleural mesothelioma.
    Cristaudo A, Foddis R, Bonotti A, Simonini S, Vivaldi A, Guglielmi G, Ambrosino N, Canessa PA, Chella A, Lucchi M, Mussi A, Mutti L.
    Int J Biol Markers; 2010 Jun 27; 25(3):164-70. PubMed ID: 20878622
    [Abstract] [Full Text] [Related]

  • 15. SFRP Tumour Suppressor Genes Are Potential Plasma-Based Epigenetic Biomarkers for Malignant Pleural Mesothelioma.
    Cheng YY, Mok E, Tan S, Leygo C, McLaughlin C, George AM, Reid G.
    Dis Markers; 2017 Jun 27; 2017():2536187. PubMed ID: 29386699
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Putative Biomarkers for Malignant Pleural Mesothelioma Suggested by Proteomic Analysis of Cell Secretome.
    Lacerenza S, Ciregia F, Giusti L, Bonotti A, Greco V, Giannaccini G, D'Antongiovanni V, Fallahi P, Pieroni L, Cristaudo A, Lucacchini A, Mazzoni MR, Foddis R.
    Cancer Genomics Proteomics; 2020 Jun 27; 17(3):225-236. PubMed ID: 32345664
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Serum biomarkers in patients with mesothelioma and pleural plaques and healthy subjects exposed to naturally occurring asbestos.
    Bayram M, Dongel I, Akbaş A, Benli I, Akkoyunlu ME, Bakan ND.
    Lung; 2014 Feb 27; 192(1):197-203. PubMed ID: 24170217
    [Abstract] [Full Text] [Related]

  • 20. Stratification of malignant pleural mesothelioma prognosis using recursive partitioning analysis.
    Suzuki H, Asami K, Hirashima T, Okamoto N, Yamadori T, Tamiya M, Morishita N, Shiroyama T, Takeoka S, Osa A, Azuma Y, Okishio K, Kawaguchi T, Atagi S, Kawase I.
    Lung; 2014 Feb 27; 192(1):191-5. PubMed ID: 24141556
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.